diabetes glp 1 agonist GLP-1 receptor agonists are increasingly used to treat type 2 and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Schematic illustration of monoagonists, dual

GLP-1RAs thus prevent the occurrence of retinal damage associated with oxidative-stress-induced activation of glial cells and collectively foster a healthy retinal microenvironment by virtue of preventing cellular overexertion [94, 100]

Addressable Market Size and Barriers to Uptake GLP-1 receptor agonist drugs are likely to completely reshape the global sugar market

The duration of effectiveness is longer

The content, opinions and statements made in this programme are those of the presenters and do not necessarily reflect the views of the supporters, editors or editorial board

The follow-up duration of these studies was variable, ranging from 16 months in the PIONEER-6 trial to 8.6 years in the SUSTAIN- 6 trial

This alarming development raises serious red flags about safety, efficacy, and ethical considerations, sounding the alarm for both consumers and healthcare professionals